Skip to main content
TipRanks
Go Ultimate75% OFF

Austar Lifesciences Ltd. (6118) Stock Price & Analysis

1 Followers

6118 Stock Chart & Stats

HK$0.51-HK$0.04(-7.34%)
At close: 4:00 PM GMT+8
HK$0.5HK$0.6HK$0.7Aug 24Sep 7Sep 21Oct 5Oct 20Nov 2Nov 16
Day’s Range
HKD 0.46 - HKD 0.52
52-Week Range
HKD 0.46 - HKD 1.08
Previous Close
HKD 0.55
Volume
N/A
Average Volume (3M)
86.40K
Market Cap
HKD 258.85M
Enterprise Value
HKD 485.11M
Total Cash (Recent Filing)
HKD 255.32M
Total Debt (Recent Filing)
HKD 268.24M
Price to Earnings (P/E)
12.8
Beta
0.80
Next Earnings
Mar 30, 2027 (Est.)
EPS Estimate
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Profitability Recovery

The return to positive EBIT, EBITDA, and net income shows that the business has regained profitability after the 2023 loss. If maintained, this recovery can support internal funding, reinforce operating resilience, and provide a more stable base for growth over the next several quarters.

Improved Balance Sheet

Lower leverage and a sizable equity base improve financial flexibility compared with 2023. This gives Austar greater capacity to absorb business volatility, fund customer-related projects, and manage obligations without relying as heavily on additional borrowing.

Positive Recent Cash Generation

Strong recent operating and free cash flow indicates that reported recovery has been accompanied by cash generation rather than relying solely on accounting earnings. This supports working-capital needs, ongoing investment, and financial flexibility across the life-sciences services business.

Bears Say

Thin Margins And Returns

Low net margin and modest ROE show that profitability remains thin relative to the company’s revenue base and capital employed. This leaves less room to absorb execution pressure or cost increases and means the earnings rebound has not yet translated into strong returns.

Uneven Revenue Growth

The uneven revenue trajectory points to limited consistency in demand or project conversion across recent years. Even with a return to growth, only modest expansion reduces operating leverage and makes it harder for Austar to build durable earnings momentum over the medium term.

Volatile Cash-Flow Track Record

Recent cash generation is encouraging, but the history of negative operating and free cash flow indicates meaningful variability in cash conversion. The 2025 decline in free cash flow reinforces that earnings recovery may not consistently translate into increasing cash available for investment or obligations.

Austar Lifesciences Ltd. News

6118 FAQ

What was Austar Lifesciences Ltd.’s price range in the past 12 months?
Austar Lifesciences Ltd. lowest stock price was HK$0.46 and its highest was HK$1.08 in the past 12 months.
What is Austar Lifesciences Ltd.’s market cap?
Austar Lifesciences Ltd.’s market cap is HK$258.85M.
When is Austar Lifesciences Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Austar Lifesciences Ltd.’s earnings last quarter?
Austar Lifesciences Ltd. released its earnings results on Aug 25, 2026. The company reported HK$0.019 earnings per share for the quarter.
Is Austar Lifesciences Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Austar Lifesciences Ltd. pay dividends?
Austar Lifesciences Ltd. pays a dividend of HK$0.05 which represents an annual dividend yield of ―. See more information on Austar Lifesciences Ltd. dividends here
What is Austar Lifesciences Ltd.’s EPS estimate?
Austar Lifesciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Austar Lifesciences Ltd. have?
Austar Lifesciences Ltd. has 512,582,030 shares outstanding.
What happened to Austar Lifesciences Ltd.’s price movement after its last earnings report?
Austar Lifesciences Ltd. reported an EPS of HK$0.019 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Austar Lifesciences Ltd.?
Currently, no hedge funds are holding shares in HK:6118
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology